Skip to main content

Lutetium Lu 177 Dotatate Dosage

Medically reviewed by Last updated on May 15, 2023.

Applies to the following strengths: 370 MBq/mL

Usual Adult Dose for Neuroendocrine Carcinoma

Intravenous infusion: 7.4 GBq (200 mCi) every 8 weeks for a total of 4 doses.

Premedication and Concomitant Medications:
Somatostatin Analogs:


Amino Acid Solution:


Use: Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

Renal Dose Adjustments

Mild to moderate renal dysfunction:

Severe renal dysfunction (CrCl less than 30 mL/min) and ESRD: Safety has not been study.

If creatinine clearance is less than 40 mL/min, 40% increase, or 40% decrease in baseline serum creatinine:

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment recommended.
Severe liver dysfunction (total bilirubin 3 times more the upper limit of normal and any AST): Safety has not been study.

If bilirubinemia is greater than 3 times the upper limit of normal (Grades 3 or 4) or hypoalbuminemia is less than 30 g/L with a decreased prothrombin ratio less than 70%:

Dose Adjustments

Thrombocytopenia Grade 2, 3 or 4:

Anemia and Neutropenia Grade 3 or 4; Other Non-Hematologic Toxicity Grade 3 or 4:


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

Reconstitution/preparation techniques:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.